WO1991006589A1 - New anti-hiv compounds belonging to aurintricarboxylic acid - Google Patents
New anti-hiv compounds belonging to aurintricarboxylic acid Download PDFInfo
- Publication number
- WO1991006589A1 WO1991006589A1 PCT/US1990/006408 US9006408W WO9106589A1 WO 1991006589 A1 WO1991006589 A1 WO 1991006589A1 US 9006408 W US9006408 W US 9006408W WO 9106589 A1 WO9106589 A1 WO 9106589A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retention time
- sec
- acid
- gpc retention
- activity
- Prior art date
Links
- GIXWDMTZECRIJT-UHFFFAOYSA-N aurintricarboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=CC1=C(C=1C=C(C(O)=CC=1)C(O)=O)C1=CC=C(O)C(C(O)=O)=C1 GIXWDMTZECRIJT-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 150000001875 compounds Chemical class 0.000 title claims abstract description 21
- 230000036436 anti-hiv Effects 0.000 title description 6
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 16
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 230000000798 anti-retroviral effect Effects 0.000 claims abstract description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 18
- 230000014759 maintenance of location Effects 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 230000001177 retroviral effect Effects 0.000 claims description 11
- CZZYITDELCSZES-UHFFFAOYSA-N diphenylmethane Chemical class C=1C=CC=CC=1CC1=CC=CC=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 8
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical class CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 7
- 150000003863 ammonium salts Chemical class 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- 238000000108 ultra-filtration Methods 0.000 claims description 6
- 230000000120 cytopathologic effect Effects 0.000 claims description 5
- 238000005194 fractionation Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 150000001555 benzenes Chemical class 0.000 claims 2
- QLQMQFUDIJFPKZ-UHFFFAOYSA-N CC1=C(C(=C(C=C1)C(C1=CC=CC=C1)C1=CC=CC=C1)C)C Chemical compound CC1=C(C(=C(C=C1)C(C1=CC=CC=C1)C1=CC=CC=C1)C)C QLQMQFUDIJFPKZ-UHFFFAOYSA-N 0.000 claims 1
- 101100172879 Caenorhabditis elegans sec-5 gene Proteins 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000000178 monomer Substances 0.000 abstract description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 5
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 31
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000007787 solid Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 7
- 235000010288 sodium nitrite Nutrition 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- AAAQKTZKLRYKHR-UHFFFAOYSA-N triphenylmethane Chemical compound C1=CC=CC=C1C(C=1C=CC=CC=1)C1=CC=CC=C1 AAAQKTZKLRYKHR-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000000538 analytical sample Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 3
- WZRZTHMJPHPAMU-UHFFFAOYSA-L disodium;(3e)-3-[(4-amino-3-sulfonatophenyl)-(4-amino-3-sulfophenyl)methylidene]-6-imino-5-methylcyclohexa-1,4-diene-1-sulfonate Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(=N)C(C)=CC1=C(C=1C=C(C(N)=CC=1)S([O-])(=O)=O)C1=CC=C(N)C(S(O)(=O)=O)=C1 WZRZTHMJPHPAMU-UHFFFAOYSA-L 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000001282 iso-butane Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 3
- UYDGECQHZQNTQS-UHFFFAOYSA-N 2-amino-4,6-dimethylpyridine-3-carboxamide Chemical compound CC1=CC(C)=C(C(N)=O)C(N)=N1 UYDGECQHZQNTQS-UHFFFAOYSA-N 0.000 description 2
- SLNKACMTMZYMNA-UHFFFAOYSA-N 3-(furan-2-yl)aniline Chemical compound NC1=CC=CC(C=2OC=CC=2)=C1 SLNKACMTMZYMNA-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000008098 formaldehyde solution Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- WHSXTWFYRGOBGO-UHFFFAOYSA-N o-cresotic acid Natural products CC1=CC=CC(C(O)=O)=C1O WHSXTWFYRGOBGO-UHFFFAOYSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 150000004961 triphenylmethanes Chemical class 0.000 description 2
- VTLSGZWUFXMAOD-UHFFFAOYSA-N (2-hydroxyphenyl)phosphonic acid Chemical compound OC1=CC=CC=C1P(O)(O)=O VTLSGZWUFXMAOD-UHFFFAOYSA-N 0.000 description 1
- PPTXVXKCQZKFBN-UHFFFAOYSA-N (S)-(-)-1,1'-Bi-2-naphthol Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3O)=C(O)C=CC2=C1 PPTXVXKCQZKFBN-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- SWHSXWLSBBYLGM-UHFFFAOYSA-N 2-[(2-carboxyphenoxy)methoxy]benzoic acid Chemical compound OC(=O)C1=CC=CC=C1OCOC1=CC=CC=C1C(O)=O SWHSXWLSBBYLGM-UHFFFAOYSA-N 0.000 description 1
- XACRYJAWPVFHLE-UHFFFAOYSA-N 4-[(3-carboxy-4-hydroxynaphthalen-1-yl)methyl]-1-hydroxynaphthalene-2-carboxylic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC(CC=3C4=CC=CC=C4C(O)=C(C(O)=O)C=3)=C21 XACRYJAWPVFHLE-UHFFFAOYSA-N 0.000 description 1
- JWQFKVGACKJIAV-UHFFFAOYSA-N 5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(CC=2C=C(C(O)=CC=2)C(O)=O)=C1 JWQFKVGACKJIAV-UHFFFAOYSA-N 0.000 description 1
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- FYEHYMARPSSOBO-UHFFFAOYSA-N Aurin Chemical compound C1=CC(O)=CC=C1C(C=1C=CC(O)=CC=1)=C1C=CC(=O)C=C1 FYEHYMARPSSOBO-UHFFFAOYSA-N 0.000 description 1
- 240000008213 Brosimum alicastrum Species 0.000 description 1
- 241001060848 Carapidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- UNPLRYRWJLTVAE-UHFFFAOYSA-N Cloperastine hydrochloride Chemical compound Cl.C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 UNPLRYRWJLTVAE-UHFFFAOYSA-N 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 241000286904 Leptothecata Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011872 intimate mixture Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- XBECFEJUQZXMFE-UHFFFAOYSA-N n-(4-aminobutyl)acetamide;hydrochloride Chemical compound Cl.CC(=O)NCCCCN XBECFEJUQZXMFE-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005828 ramon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- BLXAGSNYHSQSRC-UHFFFAOYSA-M sodium;2-hydroxybenzenesulfonate Chemical compound [Na+].OC1=CC=CC=C1S([O-])(=O)=O BLXAGSNYHSQSRC-UHFFFAOYSA-M 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/41—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton
- C07C309/42—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing singly-bound oxygen atoms bound to the carbon skeleton having the sulfo groups bound to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G8/00—Condensation polymers of aldehydes or ketones with phenols only
- C08G8/04—Condensation polymers of aldehydes or ketones with phenols only of aldehydes
- C08G8/08—Condensation polymers of aldehydes or ketones with phenols only of aldehydes of formaldehyde, e.g. of formaldehyde formed in situ
Definitions
- the present invention is related to the chemical synthesis of a substantially pure monomer of aurintricar- boxylic acid (ATA), structurally defined polymers, analogs and/or derivatives thereof and to defining anti-viral activity of the new compounds, particularly against human immunodeficiency virus (HIV) .
- ATA aurintricar- boxylic acid
- HAV human immunodeficiency virus
- ATA aurintri- carboxylic acid
- ATA is a potent inhibitor of cellular processes that depend on the binding of nucleic acids to proteins. This inhibition of the binding of nucleic acids to pro ⁇ teins may be due to the fact that the polymeric and polyanionic nature of ATA resembles the structures of oligonucleotides. To the extent that ATA occupies the oligonucleotide binding sites of a wide variety of pro ⁇ teins that normally act on oligonucleotides, it can be regarded as an oligonucleotide mimetic. Examples include the inhibition of protein synthesis by blocking the attachment of mRNA to the ribosome (Grollman et al, Proc. Natl. Acad. Sci. U.S.A.
- ATA is also known to reduce the affinity of the DNA primer for reverse transcriptase (Givens et al. Nucleic Acids Res. 1976, 3, 405), and to interfere with the activities of DNA (Seki et al, Biochem. Bioohvs. Res. Commun.
- ATA has recently been shown to block DNA-cellulose binding to progesterone, estrogen, glucocorticoid, and 1.25-dihy- droxyvita ine D3 receptors, suggesting that steroid hormone receptors and nucleic acid polymerase may have similar polynucleotide binding sites (Moudgil et al. Life Sci. 1980, 27, 1159; Moudgil et al, Archs. Biochem. Biophys. 1982, 213, 98; Mellon, Biochem. Pharmacol. 1984, 33, 1047; Moudgil et al. Steroid Biochem. 1985, 23, 125; and Moudgil et al, J. Steroid Biochem. 1985, 22, 747).
- ATA prevents the cytopathic effect of HIV-1 in ATH8 cell culture as well as the expression of. p24 in H9 cells infected with HIV-1, and it has been suggested that this effect may be due to the inhibition of HIV-1 reverse transcriptase (Balzarini et al, Biochem. Biophys. Res. Commun. 1986, 136, 64) and/or the blockade of the HIV/CD4 cell receptor (Schols et al, Proc. Natl. Acad. Sci. USA 1989, 86, 3322).
- triphenylmethane dye fuchsin acid As well as ATA, inhibit the cytopathic effect of HIV-1 in MT-4 cell culture (Baba et al, Biochem. Biophys. Res. Commun. 1988, 155, 1404).
- a still further object of the present invention is to manufacture compounds having greater potency and less cytotoxicity than ATA so as to design drugs that would be useful for the treatment of AIDS and other viral diseases.
- Figure 1 shows the originally conceived structure of triphenylmethane, and the actual polymeric form of ATA.
- Figure 2 outlines the syntheses of triphenyl carbinol.
- Figure 3 outlines the syntheses of 4,4' ,4"- trihydroxy-5,5' ,5"-tricarboxytriphenyl ethane, 5,5',5"- tricarbomethoxy-4,4',4"trihydroxytriphenylmethane, 4,4'- dihydroxy-3,3'-dimethyl-5,5'-dicarboxydiphenylmethane, 5,5 ' ,5"-trimethyl4,4' ,4"-trihydroxy-3,3' ,3"-trimethyl- triphenylcarbinol, and 5,5' ,5"- ricarbomethoxy-4,4' ,4"- trihydroxy-3,3' ,3"-trimethyltriphenylcarbinol.
- Figure 5 outlines the gel permeation chromatogra ⁇ phy fractionation of ATA.
- Figure 6 outlines the equilibrium dialylsis and ultrafiltration fractionation of ATA.
- Figures 7-25 provide in-vitro anti-HIV drug screening results for compounds described herein.
- DETAILED DESCRIPTION OF THE INVENTION The above and various other objects and advantages of the present invention are achieved by the chemical synthesis of substantially pure monomer, structurally defined polymer, analogs, fractions and derivatives of ATA, preferably having anti-viral and more preferably having anti-HIV activity.
- substantially pure as used herein means the compound is as pure as can be obtained by conventional isolation and purification means.
- the temperature was then maintained at 0°C for 1 h before the reaction mixture was left at room temperature (about 22°-24°C) for 24 h.
- the mixture was poured into crushed ice (150 g) and the precipitate was filtered and dried to give the product 4 (1.7 g, 96%) as a solid.
- the dialysis was suspended in a water jar and the water was agitated with a magnetic stirrer.
- the dialysate was replaced with fresh water several times until there was only a very faint color present in the dialysate.
- the retentate was rotary evaporated.
- the residue was dried in an Abderhalden drying pistol to obtain 290 mg of the polymeric ammonium salt of aurintri ⁇ phosphonic acid as a dark red glass.
- the retentate was rotary evaporated and the residue was dried in an Abderhalden drying pistol to afford 330 mg of red glassy solid.
- the ultra- filtrate was rotary evaporated and the residue was dried in an Abderhalden drying pistol to afford 323 mg of red glassy solid.
- EXAMPLE 16 Preparation of Polymeric Bromoaurintricarboxylic Acid (22) ATA (1.266 g) was added to glacial acetic acid (50 Ml) and the mixture was cooled in an ice bath. A mixture of bromine (0.8 Ml, density 3.11) in acetic acid (10 Ml) was added dropwise during 30 min. The reaction mixture was then left at room temperature for 22 h. The solvent was removed under reduced pressure and ice (30 g) was added. The precipitate was filtered and dried to yield bromoaurintricarboxylic acid (1.43 g) . Elemental analysis indicated that the brominated polymer contains 28.90% bromine.
- Triphenyl carbinol 12 (1.0 g) was dissolved in absolute ethanol (100 ML) and the cata ⁇ lyst Pd/C (10%, 0.3 g) was added. The contents were stirred under hydrogen atmosphere at 80 psi for 48 h.
- Frac ⁇ tionation was accomplished in a series of steps. The first of these involved separating the crude material into two components 1-067.005 and 1-067.004 (See Fig. 5). The second step involved taking these two fractions and dividing them into a second series of four components. This was accomplished by dividing the first two components into two nearly equal parts to yield compounds 1-076.001, 1-076.002, 1-076.003, and 1-076.004. The final step in the fractionation involved repeating this procedure one more time to give eight fractions 1-076.005 - 1-076.012. As is evident from the mean retention times of these eight compounds a separation of the original material based on molecular weight has been accomplished without loss of material. The sample material was converted to solid form by the following procedure.
- Antiretroviral activity of various compounds was determined by the standard assay employing CEM-V cell line and HIV-1 as the representative infecting agent and was conducted at the National Cancer Institute, Developmental Therapeutics Program, Bethesda, MD. The results are shown in various reports presented herein and made a part hereof. See Figures 7-25.
- the results presented herein indicate that the synthetic routes and the compounds described herein are useful models for the preparation of a variety of di- and tri-phenylmethanes, ATA analogs and the like which have been exemplified herein by polymeric aurin ⁇ triphosphonic, aurintrisulfonic and bromoaurintricar- boxylic acid, etc., and which possess minimal cytotoxicity but high anti-retroviral activity, particularly against HIV.
- the methodology described herein can be suitably modified for the preparation of other homogeneous polymers or compounds related to ATA and for the commer- cial scale synthesis by one of ordinary skill in the art.
- a pharmaceutical composition in accordance with the present invention comprises an effective amount of the compound of the present invention to inhibit cytopathic activity of a retrovirus and a pharmaceutically acceptable carrier.
- a method of treating retroviral infection comprises contacting retroviral-infected cells with anti ⁇ retroviral amount of the compound of the present inven ⁇ tion.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to the synthesis of compounds with anti-retroviral activity. The synthesis of substantially pure aurintricarboxylic acid monomer and structurally defined polymers, analogs and derivatives thereof, is described. The compounds are shown to have potent anti-retroviral activity, particularly against HIV-1.
Description
NEW ANTI-HIV COMPOUNDS BELONGING TO AURINTRICARBOXYLIC ACID
FIELD OF THE INVENTION The present invention is related to the chemical synthesis of a substantially pure monomer of aurintricar- boxylic acid (ATA), structurally defined polymers, analogs and/or derivatives thereof and to defining anti-viral activity of the new compounds, particularly against human immunodeficiency virus (HIV) . BACKGROUND OF THE INVENTION
Treatment of a mixture of salicylic acid and formaldehyde with sulfuric acid and sodium nitrite results in the formation of a solid substance known as aurintri- carboxylic acid (ATA) (Caro, Chem. Ber. 1892, 25, 939). This material was originally believed to have the tri- phenylmethane dye structure 1 shown in Figure 1, and this structure has persisted in the current literature even though studies reported by Gonzalez, Blackburn, and Schliech seem to indicate quite clearly that ATA is actually a heterogeneous mixture of polymers which was represented schematically as structure 2 (Gonzalez et al, T. Biochem. Biophys. Acta 1979, 562, 534), also shown in Figure 1.
ATA is a potent inhibitor of cellular processes that depend on the binding of nucleic acids to proteins. This inhibition of the binding of nucleic acids to pro¬ teins may be due to the fact that the polymeric and polyanionic nature of ATA resembles the structures of oligonucleotides. To the extent that ATA occupies the oligonucleotide binding sites of a wide variety of pro¬ teins that normally act on oligonucleotides, it can be regarded as an oligonucleotide mimetic. Examples include the inhibition of protein synthesis by blocking the attachment of mRNA to the ribosome (Grollman et al, Proc. Natl. Acad. Sci. U.S.A. 1968, 61, 719; Stewart et al, Proc. Natl. Acad. Sci. U.S.A. 1971, 68, 97; and Kreamer et al. Can. J. Biochem. 1978, 56, 1162) and inhibition of aminoacyl-tRNA synthetase (Igarashi et al. Can♦ J.
Biochem. 1975, 53, 120). ATA is also known to reduce the affinity of the DNA primer for reverse transcriptase (Givens et al. Nucleic Acids Res. 1976, 3, 405), and to interfere with the activities of DNA (Seki et al, Biochem. Bioohvs. Res. Commun. 1977, 79, 179; Tsutsui et al, Biochem Biophys. Acta 1978, 517, 14; and Nakane et al, Eur. J. Biochem. 1988, 177, 91) and RNA (Blumenthal et al, Biochem. Biophys. Res. Commun. 1973, 55, 680; Liao et al, J. Med. Chem 1975, 18, 117; and Iapalucci-Espinoza et al, Mol. Cell Biochem. 1983, 55, 41) polymerases. Ribonucleo- tide reductases from a variety of sources are inhibited uniformly by ATA (Baumann et al, Naturforsch. 1984, 39c, 276), as are an array of ribonucleases (Apirion et al. Antibiotics (NY) , 1975, 3, 327; Zuag et al. Cell, 1980, 19, 331; Gonzalez et al. Biochemistry 1980, 19, 4299; Schulz-Harder et al, Biochem. Biophys. Res. Commun. 1982, 104, 903; Ramon et al, FEMS Microbiol. Lett. 1986, 36, 9; Eslami et al, Bioche . Interna . 1986, 13, 163; and Kumar et al, Indian J. Exper. Biol. 1986, 24, 79). ATA has recently been shown to block DNA-cellulose binding to progesterone, estrogen, glucocorticoid, and 1.25-dihy- droxyvita ine D3 receptors, suggesting that steroid hormone receptors and nucleic acid polymerase may have similar polynucleotide binding sites (Moudgil et al. Life Sci. 1980, 27, 1159; Moudgil et al, Archs. Biochem. Biophys. 1982, 213, 98; Mellon, Biochem. Pharmacol. 1984, 33, 1047; Moudgil et al. Steroid Biochem. 1985, 23, 125; and Moudgil et al, J. Steroid Biochem. 1985, 22, 747).
It was recently demonstrated that ATA prevents the cytopathic effect of HIV-1 in ATH8 cell culture as well as the expression of. p24 in H9 cells infected with HIV-1, and it has been suggested that this effect may be due to the inhibition of HIV-1 reverse transcriptase (Balzarini et al, Biochem. Biophys. Res. Commun. 1986, 136, 64) and/or the blockade of the HIV/CD4 cell receptor (Schols et al, Proc. Natl. Acad. Sci. USA 1989, 86, 3322). In addition, it has been reported that the triphenylmethane dye fuchsin acid, as well as ATA, inhibit the cytopathic effect of
HIV-1 in MT-4 cell culture (Baba et al, Biochem. Biophys. Res. Commun. 1988, 155, 1404). A variety of authentic triphenylmethane dyes sharing the same skeletal structure as fuchsin acid, along with ATA, have also been reported to inhibit Raucher leukemia virus reverse transcriptase, E. coli RNA polymerase, and protein biosynthesis (Liao et al, supra) . These observations seem to contradict the conclusions of other workers "that aurintricarboxylic acid in the form of the commonly accepted structure 1 is ineffective as an inhibitor of protein nucleic acid interactions, and that the inhibitory activity of an aurintricarboxylic acid preparation is proportional to the degree of polymerization" (Gonzalez et al, supr ) . In light of such conflicting reports, the question arises as to why do non-polymeric, authentic triphenylmethane dyes inhibit protein nucleic acid interactions (Liao et al, supra) . Assuming that the known inhibition of HIV-1 reverse transcriptase by both ATA structure 2 and fuchsin acid is responsible for the observed anti-HIV activity (Balzarini et al, supra; Schols et al, supra; and Baba et al, supra) , a related question is whether or not a com¬ pound having the commonly accepted but incorrect structure 1 of ATA would have any potential as an anti-AIDS agent. In order to provide answers to such outstanding problems, one of the steps taken was to synthesize substantially pure monomer of ATA. Such a compound was not heretofore known or described.
SUMMARY OF THE INVENTION It is, therefore, an object of the present inven- tion to provide a substantially pure monomer of ATA.
It is another object of the present invention to prepare structural analogs of the monomer of ATA, includ¬ ing a variety of substituted di- and tri-phenylmethanes.
It is a further object of the present invention to synthesize homogeneous, structurally defined polymers related to ATA and to prepare structural analogs of polymeric ATA.
It is yet another object of the present invention
to fractionate polymeric ATA and polymeric ATA analogs on the basis of molecular weight and to identify the anti-HIV activity and cytotoxicity of the various fractions.
A still further object of the present invention is to manufacture compounds having greater potency and less cytotoxicity than ATA so as to design drugs that would be useful for the treatment of AIDS and other viral diseases.
Various other objects and advantages will become evident from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 shows the originally conceived structure of triphenylmethane, and the actual polymeric form of ATA. Figure 2 outlines the syntheses of triphenyl carbinol.
Figure 3 outlines the syntheses of 4,4' ,4"- trihydroxy-5,5' ,5"-tricarboxytriphenyl ethane, 5,5',5"- tricarbomethoxy-4,4',4"trihydroxytriphenylmethane, 4,4'- dihydroxy-3,3'-dimethyl-5,5'-dicarboxydiphenylmethane, 5,5 ' ,5"-trimethyl4,4' ,4"-trihydroxy-3,3' ,3"-trimethyl- triphenylcarbinol, and 5,5' ,5"- ricarbomethoxy-4,4' ,4"- trihydroxy-3,3' ,3"-trimethyltriphenylcarbinol.
Figure 4 outlines the syntheses of 5,5'-dibromo-
3,3' ,3"-dicarboxy-2 , 2'-dihydroxydiphenyl-methane, 3,3'- dicarboxy-2,2'-dihydroxydiphenylmethane, 3,3'dicarbo- methoxy-2,2'-dihydroxydiphenylmethane, aurintriphosphoric acid, and aurintrisulfonic acid.
Figure 5 outlines the gel permeation chromatogra¬ phy fractionation of ATA. Figure 6 outlines the equilibrium dialylsis and ultrafiltration fractionation of ATA.
Figures 7-25 provide in-vitro anti-HIV drug screening results for compounds described herein. DETAILED DESCRIPTION OF THE INVENTION The above and various other objects and advantages of the present invention are achieved by the chemical synthesis of substantially pure monomer, structurally defined polymer, analogs, fractions and derivatives of
ATA, preferably having anti-viral and more preferably having anti-HIV activity.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned hereunder are incorporated herein by reference. Unless mentioned otherwise, the techniques employed or contemplated herein are standard methodologies well known to one of ordinary skill in the art. The materials, methods and examples are illustrative only and not limiting.
The term "substantially pure" as used herein means the compound is as pure as can be obtained by conventional isolation and purification means.
EXAMPLE 1 Synthesis of the ATA monomer
A three step synthesis that gave the triphenylcar¬ binol 6 (ATA monomer) is depicted in Scheme I shown in Figure 2. This is the covalent hydrate of the hypotheti¬ cal structure 1, which could not be obtained despite various attempts. The successful route relied on the use of chlorine as a protecting group in order to control the regiochemistry during the first step and to prevent the further reaction of the diphenylmethane in the presence of formaldehyde and acid to form polymers of the phenol- formaldehyde type. Thus, 3-chlorosalicylic acid 3 was treated with formaldehyde and sulfuric acid to give the diphenylmethane 4. Both of the chlorine atoms present in 4 were then removed by hydrogenolysis over palladium on charcoal to afford methylene disalicylic acid 5. Reaction of intermediate 5 with salicylic acid in the presence of sulfuric acid and sodium nitrite then gave the triphenyl- carbinol 6, which' is the covalent hydrate of structure 1. The triester 7 was also prepared by treatment of 6 with
diazomethane.
EXAMPLE 2 3,3'-dichloro-5,5'-dicarboxy-4,4'-dihydroxydiphenylmethane 111 3-Chloro-salicylic acid (1.72 g, 10 mmol) was dissolved in methanol (10 mL) . Water (2.5 mL) was added and the flask was cooled to -5°C in an ice-salt bath. Concentrated sulfuric acid (30 mL) was added during 20 min. while the temperature was maintained at -5 to 0°C. The reaction mixture was then stirred at this temperature for 1 h while an aqueous solution of 37% formaldehyde (4 mL) was added. The temperature was then maintained at 0°C for 1 h before the reaction mixture was left at room temperature (about 22°-24°C) for 24 h. The mixture was poured into crushed ice (150 g) and the precipitate was filtered and dried to give the product 4 (1.7 g, 96%) as a solid. The analytical sample was recrystallized from chloroform-methanol (2:1): mp 302°C; UV (ethanol) 316 nm (8,300); IR (KBr) 3400-2850, 1680, 1610, 1460, 1290, 1235, 1170, 870, 780 cm"1; -R NMR (200 MHz, acetone-d^) δ 7.68 (s, 2 H), 7.47 (s, 2 H), 3.87 (s, 2 H) ; 13C NMR (DMSO-dβ) δ 171.53, 155.23, 135.57, 132.29, 128.77, 120.64, 114.32, 37.89; CIMS m/e. (relative intensity) 357 (MH+, 93), 339 (100). Anal. Calcd for C15H10CL2O6: C, 50.42; H, 2.80. Found: C, 50.11; H, 2.72.
3,3'-dicarboxy-4,4'-dihydroxydiphenylmethane (5
Compound 4 (1.78 g, 5 mmol) was dissolved in ethanol (30 mL) and triethylamine (15 mL) . Pd/C (10%, 500 mg) was added to the solution and the mixture was stirred under an atmosphere of hydrogen for 48 h. The catalyst was filtered off, the solvent was evaporated, and water (100 mL) was added to the residue. The solution was cooled and acidified by addition of cone, hydrochloric acid (5 mL). The white precipitate was filtered and dried to give the product 5 (1.32 g, 92%) as a solid. The analytical sample was recrystallized from chloroform- methanol (2:1): 268-269°C; UV (ethanol) 312 nm (7,530); IR (KBr) 3400, 3250-2980, 1680, 1620, 1590, 1490,
1445, 1280, 1299 cm"1; XH NMR (200 MHz, acetone-dg) δ 10.95 (s, 2 H, exchangeable with D20), 7.73 (d, 2 H, J = 2 Hz), 7.33 (dd, 2 H, J = 8 and 2 Hz), 6.88 (d 2 H, J = 8 Hz), 3.89 (s, 2 H); 13C NMR (DMSO-ds) δ 171.85, 159.55, 136.13, 132.05, 129.79, 117.28, 112.71, 38.72; CIMS m/e (relative intensity) 289 (MH+, 100), 271 (37). Anal. Calcd for C15H1206: C, 62.50; H, 4.16. Found: C, 62.67; H, 3.98.
EXAMPLE 4 3,3' ,3"-tricarboxy-4,4' ,4"-trihvdroxytriphenylcarbinol (6) Powdered sodium nitrite (0.276 g, 4 mmol) was added with vigorous stirring to concentrated sulfuric acid (3 mL) . A mixture of compound 5 (0.576 g, 2 mmol) and salicylic acid (0.276 g, 2 mmol) was added in portions. The mixture was stirred until it was homogeneous and was then poured into a solution of sodium nitrite (0.276 g, 4 mmol) in sulfuric acid (3 mL) . Stirring was then contin¬ ued at room temperature for an additional 18 h. The mixture was then poured into crushed ice (100 g) with stirring. The orange precipitate was filtered and dried to give the product 6 (0.686 g, 78%): mp 236-238°C (dec); UV (ethanol) 312 (9.935), 412 (3,425), 553 nm (10,460); IR (KBr) 3400, 3200-2840, 1670, 1610, 1575, 1480, 1430, 1350, 1290, 1200, 1130, 1070 cm-1; :H NMR (200 MNz, acetone-dg) δ 11.12 (s, 1 H, exchangeable with D20), 7.88 (3 H, d, J = 2 Hz), 7.46 (3 H, dd, J = 9 and 2 Hz), 6.92 (d, 3 H, J = 9 Hz), 5.58 (brs, exchangeable with D20); 13C NMR (acetone-dβ) δ 172.65, 161.99, 139.16, 136.45, 130.17, 117,60, 112.28, 80.59; FABMS (negative ion mode) m/e (relative intensity) 439 (M - H+, 100). EXAMPLE 5
3,3' ,3"-trimethoxycarbonyl-4,4' ,4"-trihvdroxytriphenyl¬ carbinol (7)
A solution of diazomethane in ether (20 mL, prepared from 0.824 g of nitrosomethylurea) was added to a solution of 6 (0.440 g, 1 mmol) in ether (20 mL) at 5°C and the mixture was kept at this temperature for 48 h. A few drops of acetic acid were added to the solution, the
solvent was evaporated, and the product was purified by flash chromatography over silica gel (60-200 mesh, 40g) . The analytical sample was recrystallized from hexane- methylene chloride (1:1): mp 189-190°C (dec); UV (ethanol) 312 nm (11,365); IR (KBr) 3460, 3180, 1680, 1610, 1590, 1490, 1445, 1340, 1295, 1210, 1080 cm"1; XH NMR (200 MNz, acetone-dβ) δ 10.82 (s, 3 H, exchangeable with D20); 7.78 (d, 3 H, J = 2 Hz), 7.29 (dd, 3 H, J = 9 and 2 Hz), 6.93 (d, 3 H, J - 9 Hz), 3.89 (s, 9 H) ; 10C NMR δ 170.22, 160.58, 137.38, 135.15, 128.46, 117.18, 111.57, 80.17, 52.16 cm"1; CIMS m/e (relative intensity) 483 (MH+, 54), 465 (100), 331 (16). Anal. Calcd for C25H22010: C, 62.24: H, 4.56. Found: C, 61.88; H, 4.60.
EXAMPLE 6 Synthesis of 4,4' ,4"-trihydroxy-5,5' ,5"-tricarboxytri- phenylmethane (8)
A solution of ATA monomer 6 (0.660 g., 1.5 mmols) in absolute ethanol (150 ml) was shaken under hydrogen atmosphere at 80 lbs/in2 using 10% palladium on carbon as catalyst for 72 h. The catalyst was filtered off and the solvent was removed under reduced pressure using a rota- vapor, to give 0.625 g (98%) of 4,4'4:-trihydroxy-5,5' ,5"- tricarboxy triphenylmethane: m.p. 280-282°C (decomposes). FABMS (positive ion mode) 425 (MN+, 9%); IR (KBr) 3600- 2800 (br), 1670, 1610, 1590, 1485, 1440, 1285, 1180 (br), 1070 cm-1; *H NMR (200 MHz, acetone-dβ) δ 7.65 (3 H, d, J = 2.1 Hz), 7.28 (3 H, dd, J = 8.5 and 2.3 Hz), 6.91 (3 H, d, J = 8.5 Hz), 5.51 (1 H, s); 13C-NMR (acetone-dβ) δ 172.30, 161.37, 137.47, 135.35, 131.21, 118.21, 112.84, 54.19. See Figure 3.
EXAMPLE 7 Synthesis of 5,5' ,5"-tricarbomethoxy-4,4' ,4"-trihydroxy- triphenylmethane (9)
To a solution of 8 (0.424 g, 1 mmol) in ether (20 ml), a solution of diazomethane (prepared from 0.618 g of nitrosomethyl urea in 20 ml ether) was added at 5C and kept 24 h at this temperature. A few drops of acetic acid
were added to remove excess of diazomethane. The solvent was removed under reduced pressure and the residue was chromatographed over silica gel (60-200 mesh, 20 g) using 1% ethyl acetate in dichloromethane as eluent to give 5,5'5"-tricarbomethoxy-4,4'4"trihydroxytriphenylmethane (0.355 g, 76%). The product was recrystallized from hexanedichloromethane (about 2:1): m.p. 201-202°C; CIMS (isobutane ionizing gas) 467 (MH+, 100%); IR (KBr) 3400- 3060 (br), 2960, 1675, 1610, 1585, 1480, 1435, 1335, 1290, 1260, 1200 (br), 1180, 960, 825, 780, cm-1; -K NMR (200 MHz, chloroform-d.) δ 10.72 (3H, exchanged with D20), 7.52 (3 H, d, J = 2.0 Hz), 7.18 (3 H, dd, J = 8.75 and 2.35 Hz), 6.92 (3 H, d, J = 8.5 HZ), 5.38 (1 H, s), 3.89 (9 H, s), 13C-NMR (chloroform-d) δ 170.33, 160.31, 136.41, 134.10, 129.88, 117.85, 112.18, 53.98, 52.27. See Figure 3.
EXAMPLE 8 Synthesis of 4,4'-dihvdroxy-3,3'-dimethyl-5,5'-dicarboxy diphenylmethane (11) A mixture of 3-methyl salicylic acid (7.6 g, 0.05 mole) dilute sulfuric acid (25%, 100 ml) and formaldehyde solution (37%, 4.05 mL) was heated at 90°C, with stirring. After 4 h, another 2.0 ml of formaldehyde solution was added to the reaction mixture, and the mixture was heated at 90°C for a total period of 12 h, cooled to room temper¬ ature and poured into crushed ice (100 g) . The white precipitate was filtered and dried to give 7.82 g (99%) of 11. The product was recrystallized from ethanol-chloro¬ form (1:1), m.p. 296-298°C; CIMS (isobutane ionizing gas) 317 (MH+, 56%); IR (KBr) 3500-2830 (br) , 1675, 1620, 1470, 1445, 1300 (br), 1230, 1200, 1145, 900, 790 cm"1; *H NMR (200 MHz, DMSO-dβ) δ 7.52 (2 H, S), 7.14 2 H, s), 3.77 (2 H, s), 2.19 (6 H, s). See Figure 3.
EXAMPLE 9 Synthesis of 5,5' ,5"-trimethv-4,4' ,4"-trihvdroxy-3,3' ,3"- trimethyltriphenylcarbinol (12)
Concentrated sulfuric acid (25 mL) was taken in a 100 mL round bottomed flask. Powdered sodium nitrite (2.07 g, 0.03 mole) was added slowly with stirring. An intimate mixture of 3-methyl salicylic acid (1.52 g, 0.01 mol) and 4,4'-dihydroxy-3,3'-dimethyl-5,5'-dicarboxy diphenylmethane (3.16 g, 0.01 mol) was added in small portions over a period of 20 minutes. The dark red reaction mixture was left at room temperature (~22-24C) for 16 h and then poured over crushed ice (100 g) . The precipitate was filtered and dried to give 4.32 g (90%) of (12) as a dark red powder, m.p. > 310°C: FABMS (positive ion mode) 465 (MH+-H20, 100%), FABMS (negative ion mode) 481 (M-H, 10%), 463 (M-H-H20, 100%); IR (KBr) 3400 (br) , 3100-2800 (br) 1670, 1585, 1420, 1375, 1300 (br) , 1190, 1025, 890, 785 cm"1; XH NMR (200 MHz, DMSO-dg) δ 7.50 (3 H, s), 7.24 (3 H, s) 2.17 (9 H, s), 13C-NMR (DMSO-dβ) δ 171.35, 157.57, 136.09, 134.47, 125.40, 123.54, 109.39, 77.99, 14.34. See Figure 3.
EXAMPLE 10 Synthesis of 5,5' ,5"-tricarbomethoxy-4,4' ,4"-trihvdroxy- 3,3' ,3"-trimethyltriphenylcarbinol (13 To a solution of 12 (0.974 g, 2 mmol) in methanol
(20 ml) cooled to 5°C, a solution of diazomethane in ether (25 ml, prepared from 1.545 g of nitrosomethyl urea) was added. The mixture was kept at 5°C for 48h. A few drops of acetic acid were added to remove excess of diazo- methane, solvent was removed under reduced pressure, and the residue was purified by flash column chromatography over silica gel (230-400 mesh, 20g) using dichloromethane- hexane (2:1) as- eluent. The isolated yield of the tri- methyl ester (13) is 0.650 g (62%); CIMS (isobutane ionizing gas) 525 (MH+, 8%), 507 (MH+-H20, 100%); IR (KBr)
" 3420 (br), 3180 (br), 2945, 1680, 1610, 1520, 1440, 1340,
1280, 1195, 1125, 780 cm"1; XH NMR (200 MHz, chloroform-d)
δ 11.04 (3 H, s, exchanged with D2o), 7.74 (3 H, s), 7.28 (3 H, s) 3.90 (9 H, s), 2.22 (9 H, s). See Figure 3.
EXAMPLE 11 5,5'-dibromo-3,3' ,3"-dicarboxy-2,2'-dihydroxydiphenyl- methane (15)
A stirred solution of 5-bromosalicylic acid (4,34 g, 0.02 mmol) in water (2 mL) was cooled to -5°C and concentrated sulfuric acid (80 mL) was added dropwise while the temperature was maintained between -5 and 0°C. A mixture of 38% aq formaldehyde (10 mL) and methanol (10 mL) was added to the reaction mixture over a period of 20 min. Stirring was continued for 2 h at 0°C. The reaction mixture was left at room temperature for 14 h and then poured into crushed ice. The white precipitate was filtered, washed with water, and dried to give the product 2 (4.13 g, 93%). The analytical sample was recrystallized by dissolving the solid in a minimum amount of methanol and then adding chloroform: mp 290°C (dec); IR (KBr) 3400-2800, 1655, 1600, 1445, 1425, 1285, 1230, 1170, 870, 855, 790, 675 cm"1; -H NMR (200 MHz, acetone-dg) δ 7.90 (d, 2 H, J = 2 Hz), 7.56 (d, 2 H, J=2 Hz), 4.02 (s, 2 H) ; CIMS m/e (relative intensity) 477 (MH+, 100), 429 (84), 249 (24), 231 (43), 217 (25). See Figure 4.
EXAMPLE 12 3.3'-dicarboxy-2,2'-dihydroxydiphenylmethane (16)
5,5'-Dibromo-3 ,3 '-dicarboxy-2 ,2 '-dihydroxy¬ diphenylmethane (15, 4,46 g, 0.01 mol) was dissolved in 10% alcoholic potassium hydroxide (150 mL). Palladium on activated carbon (10%, 0.5 g) was added and the solution was hydrogenated at room temperature and atmospheric pressure for 20 h. The catalyst was filtered off, the solvent evaporated, and water (100 mL) was added to the residue. The alkaline solution was cooled in an ice bath and neutralized with dilute hydrochloric acid. The precipitate was filtered, washed with water, and dried to
• give the product .4 (2.62 g, 91%). The analytical sample was recrystallized from methanol-chloroform: mp 284-
1230, 1175, 1145, 1065, 880, 740 cm"1; -K NMR (200 MHz, acetone-dg) δ 7.70 (dd. 2 H, J = 7 and 2 Hz), 7.26 (dd. 2 H, J = 7 and 2 Hz), 6.72 (t, 2 H, J = 8 Hz); CIMS m/e (relative intensity) 289 (MH+, 80), 271 (100), 151 (8), 139 (7) . See Figure 4.
EXAMPLE 13 3,3'-dicarbomethoxy-2,2'-dihydroxydiphenylmethane (17
A cooled solution of diazomethane (prepared from 0.9 g of nitroso methyl urea) in ether (20 mL) was added to a solution of 3,3'-dicarboxy-2,2'-dihydroxydi¬ phenylmethane (0.5 g, 1.74 mmol) in methanol (15 mL) at 5°C. The solution was stored in a refrigerator for 4 h. The solvent was evaporated and the residue was crystal¬ lized from chloroform-hexane to give the product 4 (0.52 g, 96%): mp 125-126°C; IR (KBr) 3400, 3080, 1660, 1605, 1430, 1285, 1245, 1190, 1140, 990, 740 cm"1; XH NMR (200 MHz, acetone-dβ) δ 7.72 (dd. 2 H, J = 8 and 2 Hz), 7.34 (dd. 2 H, J = 8 and 2 Hz), 6.84 (t, 2 H, J = 8 Hz), 4.00 (s, 2 H) , 3.94 (s, 6 H); CIMS m/e. (relative intensity) 317 (MH+, 100), 285 (35), 157 (93). See Figure 4.
EXAMPLE 14 Preparation of Ammonium Salt of Aurintriphosphonic Acid
(19)
Concentrated sulfuric acid (3.6 mL) was placed in a 25 mL two-necked flash equipped with a mechanical stirrer. The flask was cooled in a dry ice-acetone-water bath at 0-10°C and sodium nitrite (0.52 g, 7.47 mmol) was added in small portions with vigorous stirring. 2- Hydroxyphenylphosphonic acid (prepared according to: Naito et al., Shiritsu Daiσaku Yakaqakubu Kivo, 1957, 5, 43; Chem. Abstrl. 1958, 52, 6248; Freedman et al., J. Orq. Che . , I960, 25, 140) (1.30 g, 7.47 mmol) then was added in small portions with stirring. The reaction mixture became a brown solution. Formaldehyde (0.23 g of 37% solution, 2.8 mmol) was added dropwise to the flask with vigorous stirring, while the temperature of the bath was kept at -5°C. After the addition was complete, the
reaction mixture was stirred to 0-5°C for 20 min, then room temperature for another 10 min. Crushed ice (10 g) was added to the reaction mixture. The resulting mixture was a dark red solution. Extraction with ether and methylene chloride failed to separate the product from the solution.
The solution was basified with concentrated ammonium hydroxide to pH 8 to Hydrion paper. This solu¬ tion then was placed in a dialysis tube (molecular weight cut-off = 3500). The dialysis was suspended in a water jar and the water was agitated with a magnetic stirrer. The dialysate was replaced with fresh water several times until there was only a very faint color present in the dialysate. The retentate was rotary evaporated. The residue was dried in an Abderhalden drying pistol to obtain 290 mg of the polymeric ammonium salt of aurintri¬ phosphonic acid as a dark red glass.
The 1H NMR spectrum (D20) with TMS as external reference) of the red glass displayed absorptions at δ 5.50-6.80 (m) . The 13C NMR spectrum displayed absorptions at δ 27.84, 74.65, and a complex multiplet in the region at 108-150. The infrared spectrum (KBr) of this salt displayed absorptions at 3160, 1569, 1393, 1232, 1124, 1073, 1018 and 878 cm-1. EXAMPLE 15
Preparation of Ammonium Salt of Polymeric Aurintrisulfonic Acid
In a 50 mL three-necked flask equipped with a mechanical stirrer, thermometer and nitrogen gas inlet, there was placed concentrated sulfuric acid (7.4 mL) . The flask was cooled in an ice bath while sodium nitrite (1.06 g, 15.3 mmol) was added with vigorous stirring. Sodium 2- hydroxyphenylsulfonate (prepared according to: Chase et al., J. Chem. Soc. , 1963, 50) (300 g. 15.3 mmol) was added to the solution in small portions with stirring. The flask then was cooled in a dry ice-acetone-water bath. Formaldehyde (0.60 g of 37% solution, 7.4 mmol) was added to the flask with vigorous stirring while the temperature
of reaction mixture was kept below 5°C. After the addi¬ tion of formaldehyde was complete, the reaction mixture was stirred at room temp (~22-24C) for another 30 min and then poured into crushed ice (10 g) . The solution was neutralized with concentrate ammonium hydroxide. This solution then was placed in a dialysis tube (molecular weight cut-off = 3500). The dialysis tube was suspended in water and the water was agitated with a magnetic stirrer. The dialysate was replaced with fresh water several times until there was only a very faint color present in the dialysate. The retentate was rotary evaporated. The residue was dried in an Abderhalden drying pistol for 18 h to afford 400 mg of the ammonium salt of aurintrisulfonic acid (MW>3500) as a dark red glass.
The IR spectrum (KBr) of the ammonium salt of aurintrisulfonic acid (MW>3500) displaced absorptions at 3448, 3158, 1401, 1210, 1033 and 633 cm"1.
All the dialysates were collected and subjected to ultrafiltration using an Amicon pressure cell fitted with a Diaflo YC05 membrane (molecular weight cutoff = 500). The retentate was rotary evaporated and the residue was dried in an Abderhalden drying pistol to afford 330 mg of red glassy solid. This solid was dissolved in water and subjected for another ultrafiltration with a Diaflo YM2 membrane (molecular weight cutoff = 1000). Virtually all of the solution passed through this membrane. The ultra- filtrate was rotary evaporated and the residue was dried in an Abderhalden drying pistol to afford 323 mg of red glassy solid.
EXAMPLE 16 Preparation of Polymeric Bromoaurintricarboxylic Acid (22) ATA (1.266 g) was added to glacial acetic acid (50 Ml) and the mixture was cooled in an ice bath. A mixture of bromine (0.8 Ml, density 3.11) in acetic acid (10 Ml) was added dropwise during 30 min. The reaction mixture was then left at room temperature for 22 h. The solvent was removed under reduced pressure and ice (30 g) was
added. The precipitate was filtered and dried to yield bromoaurintricarboxylic acid (1.43 g) . Elemental analysis indicated that the brominated polymer contains 28.90% bromine.
EXAMPLE 17
12
3, 3 ' , 3"-tricarboxy-5,5' ,5"-trimethyl-4,4 ' ,4"- trihydroxytriphenylmethane. Triphenyl carbinol 12 (1.0 g) was dissolved in absolute ethanol (100 ML) and the cata¬ lyst Pd/C (10%, 0.3 g) was added. The contents were stirred under hydrogen atmosphere at 80 psi for 48 h. The catalyst was filtered off and the solvent was removed under reduced pressure to give 0.92 g (95%) of the triphe¬ nylmethane, which was recrystallized from chloroform- methanol: mp > 300°C (dec); IR (KBr) 3400 (br) , 3100 (br), 1660, 1605, 1470, 1430, 1265, 1180, 1125, 1005, 880, 785 cm"1; *H NMR (200 MHz, Methanol-d4) δ 7.44 (bs, 3H) , 7.13 (bs, 3H), 5.34 (s, 1H) , 2.19 (s, 9H) ; FABMS (negative ion mode) 465 (M+H, 47%), 275 (35%), 185 (100%).
EXAMPLE 18
4,4'-Methylenebis(l-hydroxy-2-naphthoic acid). A mixture of l-hydroxy-2-naphthoic acid (1,88 g, 10 mmol)
sulfuric acid (25% aq., 100 mL) and formaldehyde (37% aq. , 1.0 mL) was heated at 90°C for 6 h, left at room tempera¬ ture for 12 h, and then poured over crushed ice and the precipitate (1.82 g, 94%); filtered and dried: mp 290- 293°C (dec); IR (KBr) 3420 (br), 3080 (br) , 1665, 1645, 1590, 1520, 1465, 1300, 1260, 1160, 1100, 9915, 770 cm"1; CIMS mle (relative intensity) 389 (MH+, 9%), 345 (49%), 157 (100%); LH NMR (200 MHz, DMS0-d6) δ 8.45-8.41 (m, 2H), 7.97-7.93 (m, 2H) , 7.66-7.51 (m, 4H) , 7.37 (s, 2H) , 4.61 (s, 2H) .
EXAMPLE 19
Note: This substance was prepared by a modifica- tion of a published procedure: Artis, J. D.; Thibert,
R.J.; Mclntosh, J.M.; Zak, B. Microchem. J. 1981, 26, 487.
5,5'-Dichloro-2,2'-dihydroxy-3,3'-disulfonyloxy- diphenylmethane disodium salt. 2,2'-Methylenebis (4- chlorophenol) (8.00 g, 29.7 mmol) was dissolved in chloro- form (300 mL) in 500 mL three-necked flask equipped with a mechanical stirrer, an addition funnel, and a nitrogen inlet. A solution of chlorosulfonic acid (20.00 mL, 301 mmol) in chloroform (30 mL) was added to the flask over a period of 1 h. The reaction mixture was then stirred under a nitrogen atmosphere at room temperature for 8 h. The white solid that precipitated out of solution was collected by filtration. This solid was dissolved in water (150 mL) and then neutralized with 10% NaOH. The solution was concentrated on a rotary evaporator. The solid residue was then recrystallized from a 40% (v/v) solution of ethanol in water. The solid was collected by filtration and dried in a drying pistol for 28 h to afford the product (3.99 g, 28%): mp > 300°C; XH NMR δ 3.54 (s.
2H) , 7 . 11 (d , 2H, J=2 Hz ) , 7 . 23 (d, 2H, J=3 Hz ) ; 13C NMR δ 32 . 61 , 119 . 38 , 125 . 67 , 130 . 61 , 132 . 65 , 133 . 78 , 156 . 50 .
EXAMPLE 20 GPC fractionation of ATA GPC separations were carried out using a Shodex
GPC HF-2003 semi-prep chromatography column. Solvent consisted of 100% THF, flow rate was 3.5 mL per minute, and elution was followed by U.V. detection at a wavelength setting of 254 nm. ATA (Aldrich, 1.5 g) was dissolved in 100 mL HPLC grade THF. This solution was filtered through a medium sintered glass funnel to remove residual solids. Following a second filtration through a .45 micron nylon filter 2.0 mL samples were placed on the column. The GPC traces of these samples indicated that ATA was a mixture of polymeric components with a variety of molecular weights. The elution time for this material was 14.0 minutes wide (20 mins 00 sees - 37 mins 36 sec). Frac¬ tionation was accomplished in a series of steps. The first of these involved separating the crude material into two components 1-067.005 and 1-067.004 (See Fig. 5). The second step involved taking these two fractions and dividing them into a second series of four components. This was accomplished by dividing the first two components into two nearly equal parts to yield compounds 1-076.001, 1-076.002, 1-076.003, and 1-076.004. The final step in the fractionation involved repeating this procedure one more time to give eight fractions 1-076.005 - 1-076.012. As is evident from the mean retention times of these eight compounds a separation of the original material based on molecular weight has been accomplished without loss of material. The sample material was converted to solid form by the following procedure. Following removal of vola- tiles the residual material was taken up in ~20 mL 1:2 NH4OH:H20 and extracted three times to a total of 30 mL with methylene chloride. The aqueous layer was then acidified by the dropwise addition of 1:1 HCl (conc):H20 until solid ATA began to precipitate. After cooling in the refrigerator for several hours the ATA fraction was
recovered by filtration of the suspension through a medium sintered glass funnel. After washing with a small amount of cold water the solid was dried by storage overnight in a desiccator.
ATA was also fractionated by standard equilibrium dialysis and ultrafiltration techniques, described in Figure 6. The results are presented in Tables 1 and 2. TABLE 1 0
5
0
GPC Retention Times and Weight Distributions of Fractions Obtained by Equilibrium Dialysis and Ultrafiltration 0 Dialysis
& Ultrafiltration- GPC Analysis1- 5 Fraction MW range Weight Number Retention Area number (daltons) (%) of Peaks Time (min) (%)
0
1 Shodex HF-2003 semi-preparative column, THF solvent, flow rate 3.5 mL/min.
Antiretroviral Activity
Antiretroviral activity of various compounds was determined by the standard assay employing CEM-V cell line and HIV-1 as the representative infecting agent and was conducted at the National Cancer Institute, Developmental Therapeutics Program, Bethesda, MD. The results are shown in various reports presented herein and made a part hereof. See Figures 7-25.
In summary, the results presented herein indicate that the synthetic routes and the compounds described herein are useful models for the preparation of a variety of di- and tri-phenylmethanes, ATA analogs and the like which have been exemplified herein by polymeric aurin¬ triphosphonic, aurintrisulfonic and bromoaurintricar- boxylic acid, etc., and which possess minimal cytotoxicity but high anti-retroviral activity, particularly against HIV. Of course, the methodology described herein can be suitably modified for the preparation of other homogeneous polymers or compounds related to ATA and for the commer- cial scale synthesis by one of ordinary skill in the art.
A pharmaceutical composition in accordance with the present invention comprises an effective amount of the compound of the present invention to inhibit cytopathic activity of a retrovirus and a pharmaceutically acceptable carrier. A method of treating retroviral infection comprises contacting retroviral-infected cells with anti¬ retroviral amount of the compound of the present inven¬ tion.
It is understood that the embodiments described herein are for illustrative purposes only and that various changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.
Claims
1. A substantially pure compound having anti¬ retroviral activity, selected from the group consisting of: (a) 3, 3 ' 3"-tricarboxy-4,4 ' , 4 " -trihydroxytri- phenylcarbinol ;
( b ) 5,5' -dicarboxy-3 , 3 ' dichloro-4 , 4 ' dihydroxydi¬ phenylmethane ;
(c) 3 , 3 ' -dicarboxy-4 , 4 ' -dihydroxy-5 , 5 ' - dimethyldiphenylmethane ;
(d) 3,3' -dicarboxy-4 , 4 ' -dihydroxydinaphthyl- methane ;
( e ) 5,5' -dibromo-3 , 3 ' -dicarboxy-2 , 2 ' -dihydroxydi¬ phenylmethane ; (f) 5,5'-dichloro-2,2'-dihydroxy-3,3'-disulfonyl- oxydiphenylmethane disodium or ammonium salt;
(g) 3 , 3 ' , 3 " - tricar boxy- 4 ,4,4" -trihydroxy- triphenylmethane ;
(h) 3 , 3 ' , 3 " -tricarboxy-4 , 4 ' , 4 " -trihydroxy- 5 , 5 ' , 5 " trimethyl triphenylmethane ;
(i) polymeric aurintriphosphonic acid; (j) polymeric aurintrisulfonic acid; and (k) polymeric haloaurintricarboxylic acid.
2. A composition of matter comprising an effec- tive amount of the compound of claim 1 to inhibit retro- viral cytopathic activity and a pharmaceutically accept¬ able carrier.
3. A method of inhibiting retroviral activity, comprising contacting retroviral infected cells with an effective amount of the compound of claim 1 to inhibit retroviral activity.
4. A fractionation product of aurintricarboxylic acid polymer, said fraction having anti-retroviral activi¬ ty and the following properties as determined by equilib- rium dialysis, ultrafiltration membrane molecular weight cutoff and GPC retention time on Shodex HF-2003 semi- preparative column using THF solvent and a flow rate of 3.5 ml/min, said fraction being selected from the group consisting of:
(a) MW > 12,000, GPC retention time 27.995 - 29.024 min;
(b) 12,000>MW>7,000, GPC retention time 29.025- 29.604 min;
(c) 7,000>MW>3,500, GPC retention time 29.605- 29.754 min;
(d) 3,500>MW>2,000, GPC retention time 29.755- 29.859 min; (e) 2,000>MW>1,000, GPC retention time 29.860-
30.929 min;
(f) 1,000>MW>500, GPC retention time 30.930 min;
(g) GPC retention time 25 min 48 sec - 26min 59 sec; (h) GPC retention time 27 min 0 sec - 27 min 59 sec;
(i) GPC retention time 28 min 0 sec - 29 min 11 sec; (j) GPC retention time 29 min 12 sec - 29 min 59 sec; (k) GPC retention time 30 min 0 sec - 30 min 47 sec; and
(1) GPC retention time 30 min 48 sec
5. A composition of matter comprising an effec- tive amount of the fraction of claim 4 to inhibit retro¬ viral cytopathic activity and a pharmaceutically accept¬ able carrier.
6. A method of inhibiting retroviral activity, comprising contacting retroviral infected cells with an effective amount of the fraction of claim 4 to inhibit retroviral activity.
7. A method for the synthesis of substantially pure monomeric form of di- and tri-methylmethanes, com¬ prising the steps of: (a) reacting a halogenated benzene derivative with formaldehyde and acid to produce halogenated diphenylmethane, the halogen serving as a protecting group for controlling the regiochemistry of the reaction and for preventing polymerization of diphenylmethane;
(b) dehalogenating the halogenated diphenylmethane by hydrogenolysis in the presence of a catalyst; and then (c) reacting the dehalogenated diphenylmethane with an oxidant and a benzene derivative to obtain the desired product.
8. Use of an effective amount of the compound of claim 1 to inhibit retroviral activity.
9. Use of an effective amount of the fraction of claim 4 to inhibit retroviral activity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43156889A | 1989-11-03 | 1989-11-03 | |
US431,568 | 1989-11-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991006589A1 true WO1991006589A1 (en) | 1991-05-16 |
Family
ID=23712508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006408 WO1991006589A1 (en) | 1989-11-03 | 1990-11-05 | New anti-hiv compounds belonging to aurintricarboxylic acid |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6728290A (en) |
WO (1) | WO1991006589A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0498240A1 (en) * | 1991-02-02 | 1992-08-12 | Roche Diagnostics GmbH | Derivatives of diphenylmethane, process for their preparation and their use in supplanting iodothyronines and the proteins binding them |
WO1992013542A1 (en) * | 1991-01-31 | 1992-08-20 | Rhone-Poulenc Rorer S.A. | Application of biologically active polymers to obtain a medicament for the treatment of retrovirus infections |
EP1007068A4 (en) * | 1997-02-10 | 2001-04-25 | Laub Biochemicals Corp | Process for preparing synthetic soil-extract materials and medicaments based thereon |
EP2581080A1 (en) * | 2011-10-13 | 2013-04-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of colonisation of mucosa |
-
1990
- 1990-11-05 AU AU67282/90A patent/AU6728290A/en not_active Abandoned
- 1990-11-05 WO PCT/US1990/006408 patent/WO1991006589A1/en unknown
Non-Patent Citations (5)
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992013542A1 (en) * | 1991-01-31 | 1992-08-20 | Rhone-Poulenc Rorer S.A. | Application of biologically active polymers to obtain a medicament for the treatment of retrovirus infections |
EP0498240A1 (en) * | 1991-02-02 | 1992-08-12 | Roche Diagnostics GmbH | Derivatives of diphenylmethane, process for their preparation and their use in supplanting iodothyronines and the proteins binding them |
EP1007068A4 (en) * | 1997-02-10 | 2001-04-25 | Laub Biochemicals Corp | Process for preparing synthetic soil-extract materials and medicaments based thereon |
EP2581080A1 (en) * | 2011-10-13 | 2013-04-17 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of colonisation of mucosa |
WO2013053881A1 (en) * | 2011-10-13 | 2013-04-18 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of colonisation of mucosa |
Also Published As
Publication number | Publication date |
---|---|
AU6728290A (en) | 1991-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cushman et al. | Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogs: direct correlation of antiviral potency with molecular weight | |
Lee et al. | Antitumor agents. 111. New 4-hydroxylated and 4-halogenated anilino derivatives of 4'-demethylepipodophyllotoxin as potent inhibitors of human DNA topoisomerase II | |
Cushman et al. | Cosalane analogs with enhanced potencies as inhibitors of HIV-1 protease and integrase | |
Lin et al. | Synthesis and antiviral activity of 5-and 5'-substituted thymidine analogs | |
FI82189B (en) | FOERFARANDE FOER FRAMSTAELLNING AV EN STABIL MODIFIKATION AV TORASEMID. | |
CA1257271A (en) | 6-vinyl-furo-(3,4-c)-pyridine derivatives | |
Cushman et al. | Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds | |
IE60332B1 (en) | N-(2'aminophenyl)-benzamide-derivatives, process for their preparation and their use in the control of neoplastic diseases | |
NO147888B (en) | DOUBLE FUEL CONTROL SYSTEM FOR A GAS TURBINE. | |
US4162270A (en) | Process for producing 4,4'-dihydroxydiphenylsulfone of high purity | |
WO1994029311A1 (en) | Amino acid ester of nucleoside analogues | |
Holler et al. | Circular dichroism and ordered structure of bisnucleoside oligophosphates and their zinc (2+) and magnesium (2+) complexes | |
JPH02157273A (en) | Arylalkoxycoumarine, production thereof, and remedy | |
WO1991006589A1 (en) | New anti-hiv compounds belonging to aurintricarboxylic acid | |
JPH01230519A (en) | Use of polysulfated heparin | |
US3567777A (en) | 4-chloro-5-sulfamyl salicylic acid-(2',6'-dimethyl) anilide | |
Roblin Jr et al. | Studies in Chemotherapy. IV. Sulfanilamidopyrimidines1 | |
US4691012A (en) | Sialic acid derivative and process for preparing the same | |
Fox et al. | Enzymic Synthesis of Peptide Bonds. VI. The Influence of Residue Type on Papaincatalyzed Reactions of Some Benzoylamino Acids with Some Amino Acid Anilides1, 2 | |
Heindel et al. | Hydrazide pharmaceuticals as conjugates to polyaldehyde dextran: syntheses, characterization, and stability | |
Schwarz et al. | THREE MINOR ALKALOIDS OF GELSEMIUM SEMPERVIRENS AIT. | |
JPH06501690A (en) | Use of thiazoloisoindolinone derivatives as antiviral drugs | |
SU1375131A3 (en) | Method of producing derivatives of n-benzoyl-nъ-pyrimidinyloxyphenylcarbamide | |
US2584024A (en) | 2,4,5-triamino-6-alkoxy pyrimidines and process of preparing same | |
Kang et al. | Design of structure-based reverse transcriptase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
NENP | Non-entry into the national phase |
Ref country code: CA |